Most Read Articles

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA

Meghna Jani, William G Dixon, Lianne Kersley-Fleet, Ian N Bruce, Hector Chinoy, Anne Barton, Mark Lunt, Kath Watson, BSRBR-RA*, BSRBR-RA Control Centre Consortium*, Deborah P Symmons, Kimme L Hyrich, BSRBR-RA, BSRBR-RA Control Centre Consortium, Nicola Maiden, Tom Price, Neil Hopkinson, Sheila O'Reilly, Lesley Hordon, Ian Griffiths, Duncan Porter, Hilary Capell, Andy Hassell, Romela Benitha, Ernest Choy, David Walsh, Paul Emery, Susan Knight, Allister Taggart, David Scott, Paul Thompson, Fiona McCrae, Rhian Goodfellow, George Kitas, Ronald Jubb, Rikki Abernethy, Shane Clarke, Sandra Green, Paul Sanders, Amanda Coulson, Bev Harrison, Marwan Bukhari, Peter Klimiuk


January 17, 2017